NCT00109863View on ClinicalTrials.gov

Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

February 28, 2014

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

hu14.18-IL2 fusion protein

Trial Locations (1)

53792-6164

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Wisconsin, Madison

OTHER

NCT00109863 - Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma | Biotech Hunter | Biotech Hunter